PFE · News · 20261104N
Guidance / Outlook
PFIZER INC · 2026-11-04 · Importance 63 · Surprise 60 · In source text
Pfizer raised its 2026 revenue forecast to $62 billion–$64 billion and adjusted diluted EPS forecast to $2.95–$3.05. Q3 2026 revenue was $16.6 billion and adjusted diluted EPS was $0.87, including a $0.10 Innovent transaction charge. Management attributed the guidance increase to performance through Q3 and confidence in execution.
Key facts
- Pfizer raised its 2026 revenue outlook to $62 billion–$64 billion and its adjusted EPS outlook to $2.95–$3.05. source
- Pfizer is targeting a high-single-digit revenue CAGR from 2028 through 2033. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | committed | — | Pfizer raised its 2026 revenue outlook to $62 billion–$64 billion and its adjusted EPS outlook to $2.95–$3.05. |
| net_income | positive | committed | — | Pfizer raised its 2026 revenue outlook to $62 billion–$64 billion and its adjusted EPS outlook to $2.95–$3.05. |
| revenue | positive | contingent | — | Pfizer is targeting a high-single-digit revenue CAGR from 2028 through 2033. |